{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:41Z","timestamp":1794047441077,"version":"4.8.0"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) cells are highly dependent on interactions with the immunosuppressive tumor microenvironment (TME) for survival and proliferation. In the search for novel treatments, pro-inflammatory cytokines have emerged as candidates to reactivate the immune system. Among those, interleukin 27 (IL-27) has recently gained attention, but its effects differ among malignancies. Here, we utilized the E\u03bc-TCL1 and EBI3 knock-out mouse models as well as clinical samples from patients to investigate the role of IL-27 in CLL. Characterization of murine leukemic spleens revealed that the absence of IL-27 leads to enhanced CLL development and a more immunosuppressive TME in transgenic mice. Gene-profiling of T-cell subsets from EBI3 knock-out highlighted transcriptional changes in the CD8+ T-cell population associated with T-cell activation, proliferation, and cytotoxicity. We also observed an increased anti-tumor activity of CD8+ T cells in the presence of IL-27 ex vivo with murine and clinical samples. Notably, IL-27 treatment led to the reactivation of autologous T cells from CLL patients. Finally, we detected a decrease in IL-27 serum levels during CLL development in both pre-clinical and patient samples. Altogether, we demonstrated that IL-27 has a strong anti-tumorigenic role in CLL and postulate this cytokine as a promising treatment or adjuvant for this malignancy.<\/jats:p>","DOI":"10.3324\/haematol.2022.282474","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T03:46:26Z","timestamp":1687405586000},"page":"3011-3024","source":"Crossref","is-referenced-by-count":18,"title":["Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia"],"prefix":"10.3324","volume":"108","author":[{"given":"Giulia","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria Fernandez","family":"Botana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Wierz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp M.","family":"Roessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangda","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheed","family":"Al-Hity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Gonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Seiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Largeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Moussay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Paggetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"53666","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"53667","doi-asserted-by":"crossref","unstructured":"Cree IA. The WHO classification of haematolymphoid tumours. Leukemia. 2022; 36(7):1701-1702.","DOI":"10.1038\/s41375-022-01625-x"},{"key":"53668","doi-asserted-by":"crossref","unstructured":"Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020; 383(5):460-473.","DOI":"10.1056\/NEJMra1908213"},{"key":"53669","doi-asserted-by":"crossref","unstructured":"Svanberg R, Janum S, Patten PEM, Ramsay AG, Niemann CU. Targeting the tumor microenvironment in chronic lymphocytic leukemia. Haematologica. 2021; 106(9):2312-2324.","DOI":"10.3324\/haematol.2020.268037"},{"key":"53670","doi-asserted-by":"crossref","unstructured":"Largeot A, Klapp V, Viry E. Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as therapeutic strategy in CLL. Blood. 2023; 141(26):3166-3183.","DOI":"10.1182\/blood.2022017839"},{"key":"53671","doi-asserted-by":"crossref","unstructured":"Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol. 1989; 71(3):343-350.","DOI":"10.1111\/j.1365-2141.1989.tb04290.x"},{"key":"53672","doi-asserted-by":"crossref","unstructured":"Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000; 96(8):2655-2663.","DOI":"10.1182\/blood.V96.8.2655.h8002655_2655_2663"},{"key":"53673","doi-asserted-by":"crossref","unstructured":"Asslaber D, Gr\u00f6ssinger EM, Girbl T. Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?. Br J Haematol. 2013; 160(5):711-714.","DOI":"10.1111\/bjh.12151"},{"key":"53674","doi-asserted-by":"crossref","unstructured":"Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol. 2015; 33:417-443.","DOI":"10.1146\/annurev-immunol-032414-112134"},{"key":"53675","doi-asserted-by":"crossref","unstructured":"Molle C, Nguyen M, Flamand V. IL-27 Synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. J Immunol. 2007; 178(12):7607-7615.","DOI":"10.4049\/jimmunol.178.12.7607"},{"key":"53676","doi-asserted-by":"crossref","unstructured":"Fabbi M, Carbotti G, Ferrini S. Dual roles of IL-27 in cancer biology and immunotherapy. Mediators Inflamm. 2017; 2017:3958069.","DOI":"10.1155\/2017\/3958069"},{"key":"53677","doi-asserted-by":"crossref","unstructured":"Kourko O, Seaver K, Odoardi N, Basta S, Gee K. IL-27, IL-30, and IL-35: a cytokine triumvirate in cancer. Front Oncol. 2019; 9:969.","DOI":"10.3389\/fonc.2019.00969"},{"key":"53678","doi-asserted-by":"crossref","unstructured":"Hisada M, Kamiya S, Fujita K. Potent antitumor activity of interleukin-27. Cancer Res. 2004; 64(3):1152-1156.","DOI":"10.1158\/0008-5472.CAN-03-2084"},{"key":"53679","unstructured":"Liu Z, Yu J, Carson WE, Bai XF. The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. Am J Transl Res. 2013; 5(5):470-480."},{"key":"53680","doi-asserted-by":"crossref","unstructured":"Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, Yoshimoto T. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol. 2005; 175(3):1686-1693.","DOI":"10.4049\/jimmunol.175.3.1686"},{"key":"53681","doi-asserted-by":"crossref","unstructured":"Salcedo R, Stauffer JK, Lincoln E. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol. 2004; 173(12):7170-7182.","DOI":"10.4049\/jimmunol.173.12.7170"},{"key":"53682","doi-asserted-by":"crossref","unstructured":"Matsui M, Kishida T, Nakano H. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 2009; 69(6):2523-2530.","DOI":"10.1158\/0008-5472.CAN-08-2793"},{"key":"53683","doi-asserted-by":"crossref","unstructured":"Yao L, Wang M, Niu Z. Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages. Cytokine. 2017; 89:194-200.","DOI":"10.1016\/j.cyto.2015.12.003"},{"key":"53684","unstructured":"Diakowska D, Lewandowski A, Markocka-M\u0105czka K, Grabowski K. Concentration of serum interleukin-27 increase in patients with lymph node metastatic gastroesophageal cancer. Adv Clin Exp Med. 2013; 22(5):683-691."},{"key":"53685","doi-asserted-by":"crossref","unstructured":"Gonin J, Carlotti A, Dietrich C. Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected]. PLoS One. 2013; 8(10):e75694.","DOI":"10.1371\/journal.pone.0075694"},{"key":"53686","doi-asserted-by":"crossref","unstructured":"Ahmed HA, Maklad AM, Khaled SA, Elyamany A. Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers. J Blood Med. 2019; 10:341-349.","DOI":"10.2147\/JBM.S221301"},{"key":"53687","doi-asserted-by":"crossref","unstructured":"Carbotti G, Barisione G, Airoldi I. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. 2015; 6(41):43267-43280.","DOI":"10.18632\/oncotarget.6530"},{"key":"53688","doi-asserted-by":"crossref","unstructured":"Chihara N, Madi A, Kondo T. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018; 558(7710):454-459.","DOI":"10.1038\/s41586-018-0206-z"},{"key":"53689","doi-asserted-by":"crossref","unstructured":"Sawant DV, Yano H, Chikina M. Adaptive plasticity of IL-10(+) and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019; 20(6):724-735.","DOI":"10.1038\/s41590-019-0346-9"},{"key":"53690","doi-asserted-by":"crossref","unstructured":"Palma M, Gentilcore G, Heimersson K. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017; 102(3):562-572.","DOI":"10.3324\/haematol.2016.151100"},{"key":"53691","doi-asserted-by":"crossref","unstructured":"Schoppmeyer R, Zhao R, Cheng H. Human profilin 1 is a negative regulator of CTL mediated cell-killing and migration. Eur J Immunol. 2017; 47(9):1562-1572.","DOI":"10.1002\/eji.201747124"},{"key":"53692","doi-asserted-by":"crossref","unstructured":"Ren W, Liu G, Yin J. Amino-acid transporters in T-cell activation and differentiation. Cell Death Dis. 2017; 8(3):e2655.","DOI":"10.1038\/cddis.2016.222"},{"key":"53693","doi-asserted-by":"crossref","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS. Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020; 52(5):825-841.","DOI":"10.1016\/j.immuni.2020.04.014"},{"key":"53694","doi-asserted-by":"crossref","unstructured":"Kachroo P, Lee MH, Zhang L. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res. 2013; 32(1):97.","DOI":"10.1186\/1756-9966-32-97"},{"key":"53695","doi-asserted-by":"crossref","unstructured":"Manouchehri-Doulabi E, Abbaspour S, Rostami S. Evaluating the mechanism underlying antitumor effect of interleukin 27 on B cells of chronic lymphocytic leukemia patients. J Cell Physiol. 2020; 235(12):9424-9431.","DOI":"10.1002\/jcp.29747"},{"key":"53696","doi-asserted-by":"crossref","unstructured":"Hemati M, Rasouli Nejad Z, Shokri MR, Ghahremanfard F, Mir Mohammadkhani M, Kokhaei P. IL-27 impact on NK cells activity: Implication for a robust anti-tumor response in chronic lymphocytic leukemia. Int Immunopharmacol. 2020; 82:106350.","DOI":"10.1016\/j.intimp.2020.106350"},{"key":"53697","doi-asserted-by":"crossref","unstructured":"Jia H, Dilger P, Bird C, Wadhwa M. IL-27 promotes proliferation of human leukemic cell lines through the MAPK\/ERK signaling pathway and suppresses sensitivity to chemotherapeutic drugs. J Interferon Cytokine Res. 2016; 36(5):302-316.","DOI":"10.1089\/jir.2015.0091"},{"key":"53698","doi-asserted-by":"crossref","unstructured":"Gargiulo E, Viry E, Morande PE. Extracellular vesicle secretion by leukemia cells in vivo promotes CLL progression by hampering antitumor T-cell responses. Blood Cancer Discov. 2023; 4(1):54-77.","DOI":"10.1158\/2643-3230.BCD-22-0029"},{"key":"53699","doi-asserted-by":"crossref","unstructured":"Wierz M, Pierson S, Guyonnet L. Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood. 2018; 131(14):1617-1621.","DOI":"10.1182\/blood-2017-06-792267"},{"key":"53700","doi-asserted-by":"crossref","unstructured":"Lu D, Zhou X, Yao L, Liu C, Jin F, Wu Y. Clinical Implications of the interleukin 27 serum level in breast cancer. J InvestMed. 2014; 62(3):627-631.","DOI":"10.2310\/JIM.0000000000000046"},{"key":"53701","doi-asserted-by":"crossref","unstructured":"Duan M, Ning Z, Fu Z. Decreased IL-27 negatively correlated with Th17 cells in non-small-cell lung cancer patients. Mediators Inflamm. 2015; 2015:802939.","DOI":"10.1155\/2015\/802939"},{"key":"53702","doi-asserted-by":"crossref","unstructured":"Zorzoli A, Di Carlo E, Cocco C. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD\/SCID\/Il2rg-\/- mice. Clin Cancer Res. 2012; 18(6):1630-1640.","DOI":"10.1158\/1078-0432.CCR-11-2432"},{"key":"53703","doi-asserted-by":"crossref","unstructured":"Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?. Leukemia. 2020; 34(8):2012-2024.","DOI":"10.1038\/s41375-020-0873-2"},{"key":"53704","doi-asserted-by":"crossref","unstructured":"Takeda A, Hamano S, Yamanaka A. Cutting edge: role of IL-27\/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol. 2003; 170(10):4886-4890.","DOI":"10.4049\/jimmunol.170.10.4886"},{"key":"53705","doi-asserted-by":"crossref","unstructured":"Salcedo R, Hixon JA, Stauffer JK. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol. 2009; 182(7):4328-4338.","DOI":"10.4049\/jimmunol.0800471"},{"key":"53706","doi-asserted-by":"crossref","unstructured":"Mayer KD, Mohrs K, Reiley W. Cutting Edge: T-bet and IL-27R are critical for in vivo IFN-\u03b3 production by CD8 T cells during infection. J Immunol. 2008; 180(2):693-697.","DOI":"10.4049\/jimmunol.180.2.693"},{"key":"53707","doi-asserted-by":"crossref","unstructured":"Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. IL-27 increases the proliferation and effector functions of human na\u00efve CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol. 2011; 41(1):47-59.","DOI":"10.1002\/eji.201040804"},{"key":"53708","doi-asserted-by":"crossref","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS. Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020; 52(5):825-841.e8.","DOI":"10.1016\/j.immuni.2020.04.014"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282474\/75712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282474\/76221","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11124\/75712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:19Z","timestamp":1794045859000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282474","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,22]]}}}